Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Conditions

Pulmonary Disease, Chronic Obstructive

Keywords

mortality, TORCH, SERETIDE, ADVAIR, COPD

Brief summary

The purpose of this study is to see if fluticasone 500mcg/salmeterol 50mcg can improve the survival of subjects with COPD and also assess the long term safety profile of this drug.

Detailed description

A multicenter, randomized, double-blind, parallel group, placebo controlled study to investigate the effects of salmeterol/fluticasone 50/500mcg bd, salmeterol 50mcg bd, and fluticasone 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease over 3 years of treatment.

Nawar Diar Bakerly, Kirill Nikitin, Neil G. Snowise, Glenn Cardwell, Daryl Freeman et al. (7 authors)

BMJ Open Respiratory Research2022-09-013 citations

10.1136/bmjresp-2022-001303

Risk factors for exacerbations and pneumonia in patients with chronic obstructive pulmonary disease: a pooled analysis.

Hartley BF, Barnes NC, Lettis S, Compton CH, Papi A, Jones P.

2020-01-0620 citations

10.1186/s12931-019-1262-0

<p>Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study</p>

Victoria Federico Paly, Ian Naya, Necdet B. Gunsoy, Maurice T. Driessen, Nancy Risebrough et al. (7 authors)

International Journal of COPD2019-05-017 citations

10.2147/copd.s188898

Long-term outcomes following first short-term clinically important deterioration in COPD

Ian Naya, Lee Tombs, Hana Muellerova, Christopher Compton, Paul Jones

Respiratory Research2018-11-1941 citations

10.1186/s12931-018-0928-3

P250 Informing the pathway of COPD treatment (the IMPACT study): single inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with COPD – cost-effectiveness in the UK

Agnès Martin, Drishti Shah, Maik Schroeder, Kerigo Ndirangu, N Risebrough et al. (9 authors)

2018-11-161 citations

10.1136/thorax-2018-212555.406

P249 Informing the pathway of COPD treatment (the IMPACT study): single inhaler triple therapy (FF/UMEC/VI) versus dual bronchodilator therapy (UMEC/VI) in patients with COPD – cost-effectiveness in the UK

G Anley, Drishti Shah, Maik Schroeder, Kerigo Ndirangu, N Risebrough et al. (9 authors)

2018-11-161 citations

10.1136/thorax-2018-212555.405

Economic and quality of life consequences of clinically important deterioration in patients with COPD: results from the TORCH study

Afisi Ismaila, Maurice T. Driessen, Andrew Briggs, Nancy Risebrough, Ian Naya et al. (7 authors)

2018-09-15

10.1183/13993003.congress-2018.oa1660

Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β<sub>2</sub>-Agonist Therapy: An Integrated Post Hoc Analysis.

Naya IP, Tombs L, Lipson DA, Compton C.

2018-09-0612 citations

10.1007/s12325-018-0771-4

Long-term outcome following first clinically important deterioration in COPD

I. Méndez Naya, Lee Tombs, Hana Müllerová, Chris Compton, Paul Jones

2016-09-018 citations

10.1183/13993003.congress-2016.pa304

Health status in the TORCH study of COPD: treatment efficacy and other determinants of change.

Jones PW, Anderson JA, Calverley PM, Celli BR, Ferguson GT, Jenkins C, Yates JC, Vestbo J, Spencer MD, TORCH investigators.

2011-05-3156 citations

10.1186/1465-9921-12-71

Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience.

Celli B, Vestbo J, Jenkins CR, Jones PW, Ferguson GT, Calverley PM, Yates JC, Anderson JA, Willits LR, Wise RA, Investigators of the TORCH Study.

2010-09-02135 citations

10.1164/rccm.201004-0665oc

Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study.

Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, Yates JC, Willits LR, Vestbo J.

2009-06-30233 citations

10.1186/1465-9921-10-59

Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.

Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM.

2008-05-29512 citations

10.1164/rccm.200712-1869oc

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.

Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, TORCH investigators.

2007-02-012,152 citations

10.1056/nejmoa063070

Interventions

DRUGSalmeterol 50mcg/ Fluticasone Propionate 500mcg

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

40 Years to 80 Years

Healthy volunteers

No

Inclusion criteria

* Patients with COPD and FEV1 \<60% of predicted normal and baseline (pre-bronchodilator) FEV1/FVC ratio \<70%. * Current or ex-smokers with a smoking history of at least 10 pack-years.

Exclusion criteria

* Diagnosis of other respiratory disorders (including asthma). * Requirement for long term oxygen therapy.

Design outcomes

Primary

Measure	Time frame
All cause mortality at 3 years	—

Secondary

Measure	Time frame
Rate of moderate and severe COPD exacerbations and health status assessed by the St. George's Respiratory Questionnaire.	—

Countries

Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, Iceland, Italy, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Pakistan, Philippines, Poland, Puerto Rico, Romania, Russia, Singapore, Slovakia, South Africa, Spain, Sweden, Taiwan, Thailand, Ukraine, United Kingdom, United States

Outcome results

None listed